Biotech ETF Rises as Vertex Gains 6.3% on 52% UPCR Reduction
Vertex Pharmaceuticals’ Phase 3 RAINIER trial of povetacicept in IgA nephropathy achieved a 52% UPCR reduction at Week 36 versus placebo, prompting an FDA rolling review and a planned full BLA submission by month-end. The drugmaker’s shares jumped 6.32% premarket, a key catalyst for VanEck Biotech ETF’s 9.12% weighting in the company.
1. Phase 3 RAINIER Trial Results
Vertex’s Phase 3 RAINIER trial of povetacicept met its primary endpoint, with a 52% reduction in urine protein to creatinine ratio at Week 36 and a 49.8% decrease versus placebo. The trial also showed a 77.4% reduction in serum galactose-deficient IgA1 and hematuria resolution in 85.1% of patients. These data support a rolling FDA review and a planned full BLA submission by the end of March.
2. Vertex Stock Reaction
In premarket trading, Vertex shares jumped 6.32% following the interim trial data, pushing the stock above its 20-day and 100-day averages. Technical indicators remain mixed, with a neutral RSI of 44.6 and MACD below its signal line, indicating potential consolidation after the rally.
3. Impact on VanEck Biotech ETF
Vertex comprises 9.12% of VanEck Biotech ETF, making its share movement a significant driver of the fund’s performance. Positive trial developments and share gains in a top holding could boost the ETF’s NAV and attract inflows from investors seeking biotech exposure.